Evogene (EVGN) Amortization of Deferred Charges (2013 - 2023)
Evogene (EVGN) posted Amortization of Deferred Charges of $60000.0 for Q2 2023, down 97.05% sequentially from $2.0 million in Q2 2022, and down 97.05% YoY from $2.0 million in Q2 2022.
Evogene (EVGN) Amortization of Deferred Charges (2013 - 2023) Analysis & Trends
Evogene has reported Amortization of Deferred Charges for 6 years, with the latest figure at $60000.0 in Q2 2023.
- Quarterly Amortization of Deferred Charges fell 97.05% year-over-year to $60000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $3.4 million (down 0.83% YoY) and the FY2022 annual result came in at $3.0 million, changed N/A from the prior year.
- Amortization of Deferred Charges declined to $60000.0 in Q2 2023 per EVGN's latest filing, from $2.0 million in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $2.0 million in Q2 2022 and troughed at $60000.0 in Q2 2023.
- A 5-year average of $688600.0 and a median of $376000.0 in 2020 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2021 and 2023: Amortization of Deferred Charges soared 135.64% in 2021, then tumbled 97.05% in 2023.
- Over 5 years, Amortization of Deferred Charges stood at $88000.0 in 2019, then jumped by 327.27% to $376000.0 in 2020, then jumped by 135.64% to $886000.0 in 2021, then jumped by 129.46% to $2.0 million in 2022, then sank by 97.05% to $60000.0 in 2023.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $60000.0, $2.0 million, and $886000.0 for Q2 2023, Q2 2022, and Q1 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 60,000.00 |
| Jun 30, 2023 | 60,000.00 |
| Jun 30, 2022 | 2.03 Mn |
| Jun 30, 2022 | 2.03 Mn |
| Mar 31, 2021 | 886,000.00 |
| Mar 31, 2021 | 886,000.00 |
| Mar 31, 2020 | 376,000.00 |
| Mar 31, 2020 | 376,000.00 |
| Dec 31, 2019 | 88,000.00 |
| Dec 31, 2019 | 88,000.00 |
| Dec 31, 2013 | 1.04 Mn |
| Dec 31, 2013 | 1.04 Mn |
| Sep 30, 2013 | -270,000.00 |
| Sep 30, 2013 | -270,000.00 |
| Jun 30, 2013 | -550,000.00 |
| Jun 30, 2013 | -550,000.00 |